References
1. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint
signaling inhibition for cancer immunotherapy: mechanism, combinations,
and clinical outcome. Frontiers in pharmacology . 2017;8:561.
2. McLachlan J. Immune checkpoint inhibitors and their side effects.Pathology . 2019;51:S17.
3. Baxi S, Yang A, Gennarelli RL, et al. Immune-related adverse events
for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.Bmj . 2018;360
4. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors.American journal of clinical dermatology . 2018;19(3):345-361.
5. Naidoo J, Page D, Li BT, et al. Toxicities of the anti-PD-1 and
anti-PD-L1 immune checkpoint antibodies. Annals of Oncology .
2015;26(12):2375-2391.
6. Belum V, Benhuri B, Postow M, et al. Characterisation and management
of dermatologic adverse events to agents targeting the PD-1 receptor.European journal of cancer . 2016;60:12-25.
7. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Peñas P. A case of
bullous pemphigoid in a patient with metastatic melanoma treated with
pembrolizumab. Melanoma research . 2015;25(3):265-268.
8. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse
effects of the immune checkpoint inhibitors. Current problems in
cancer . 2017;41(2):125-128.
9. Miraglia E, Soda G, Giustini S. Genital lichen sclerosus after
nivolumab. Dermatology Online Journal . 2020;26(11)
10. Lee M, Seetharamu N. An atypical presentation of lichen planus-like
reaction from pembrolizumab. Case reports in dermatological
medicine . 2019;2019
11. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP.
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint
antibodies. Current opinion in oncology . 2016;28(4):254-263.
12. Yılmaz M, Güven Meşe Ş, Çelik U. Nivolumab-induced lichen planus.
2020;
13. Veronesi G, Scarfì F, Misciali C, et al. An unusual skin reaction in
uveal melanoma during treatment with nivolumab: extragenital lichen
sclerosus. Anti-cancer drugs . 2019;30(9):969-972.
14. Nguyen ED, Xue YK, Danesh M, et al. A Case of Nivolumab-Induced
Cutaneous Toxicity with Multiple Morphologies. Dermatopathology .
2019;6(4):255-259.
15. van Damme C, Sibaud V, André J, Richert B, Berlingin E.
Anti-programmed cell death protein 1-induced lichenoid changes of the
nail unit: Histopathologic description. JAAD Case Reports .
2021;10:110.
16. Ferguson L, Ho B, Weir J, et al. Extensive mucocutaneous,
oesophageal and otic lichen planus secondary to nivolumab therapy.Skin Health and Disease . 2021;1(1):e8.
17. Liu R, Consuegra G, Chou S, Fernandez Penas P. Vitiligo‐like
depigmentation in oncology patients treated with immunotherapies for
nonmelanoma metastatic cancers. Clinical and experimental
dermatology . 2019;44(6):643-646.
18. Kwon CW, Murthy RK, Kudchadkar R, Stoff BK. Pembrolizumab-induced
lichen planus pemphigoides in a patient with metastatic Merkel cell
carcinoma. JAAD Case Reports . 2020;6(10):1045-1047.
19. Coscarart A, Martel J, Lee MP, Wang AR. Pembrolizumab‐induced
pseudoepitheliomatous eruption consistent with hypertrophic lichen
planus. Journal of cutaneous pathology . 2020;47(3):275-279.
20. Chapman S, Ashack K, Dapprich DC. Hypertrophic Lichen Planus–like
Eruption Following Pembrolizumab. Cutis . 2021;107(1):E10-E11.
21. Sethi A, Raj M. Pembrolizumab-Induced Lichenoid Dermatitis in a
Patient With Metastatic Cancer of Unknown Primary. Cureus .
2021;13(3)
22. Fixsen E, Patel J, Selim MA, Kheterpal M. Resolution of
Pembrolizumab‐Associated Steroid‐Refractory Lichenoid Dermatitis with
Cyclosporine. The oncologist . 2019;24(3):e103.
23. Sugawara A, Koga H, Abe T, Ishii N, Nakama T. Lichen planus‐like
lesion preceding bullous pemphigoid development after programmed cell
death protein‐1 inhibitor treatment. The Journal of dermatology .
2021;48(3):401-404.
24. Esfahani K, Berg M-HH, Zargham H, et al. Narrowband ultraviolet B
therapy for refractory immune-related lichenoid dermatitis on PD-1
therapy: a case report. Journal for immunotherapy of cancer .
2021;9(3)
25. Marques‐Piubelli ML, Tetzlaff MT, Nagarajan P, et al. Hypertrophic
lichenoid dermatitis immune‐related adverse event during combined immune
checkpoint and exportin inhibitor therapy: A diagnostic pitfall for
superficially invasive squamous cell carcinoma. Journal of
cutaneous pathology . 2020;47(10):954-959.
26. Cardis MA, Jiang H, Strauss J, Gulley JL, Brownell I. Diffuse lichen
planus-like keratoses and clinical pseudo-progression associated with
avelumab treatment for Merkel cell carcinoma, a case report. BMC
cancer . 2019;19(1):1-5.
27. Manko S, Côté B, Provost N. A case of durvalumab-induced lichenoid
eruption evolving to bullous eruption after phototherapy: A case report.SAGE open medical case reports . 2021;9:2050313X21993279.
28. Myrdal CN, Sundararajan S, Curiel-Lewandrowski C. Widespread
Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1
Blockade. Case Reports in Dermatology . 2020;12(2):119-123.
29. Shakhbazova A, Hinds B, Marsch AF. Lichenoid inflammation of DSAP
lesions following treatment with durvalumab, olaparib and paclitaxel: A
potential diagnostic pitfall mimicking lichenoid drug eruptions
associated with PDL-1 inhibitors. Dermatology Online Journal .
2020;26(3)
30. Danlos F-X, Pagès C, Baroudjian B, et al. Nivolumab-induced
sarcoid-like granulomatous reaction in a patient with advanced melanoma.Chest . 2016;149(5):e133-e136.
31. Montaudié H, Pradelli J, Passeron T, Lacour JP, Leroy S. Pulmonary
sarcoid‐like granulomatosis induced by nivolumab. British Journal
of Dermatology . 2017;176(4):1060-1063.
32. Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA,
Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors.Journal of Thoracic Oncology . 2018;13(8):1076-1082.
33. Diaz‐Perez JA, Beveridge MG, Victor TA, Cibull TL. Granulomatous and
lichenoid dermatitis after IgG4 anti‐PD‐1 monoclonal antibody therapy
for advanced cancer. Journal of cutaneous pathology .
2018;45(6):434-438.
34. Honigman AD, Lai F, Elakis J, Prall O, Goh M, McCormack C.
Pembrolizumab-induced sarcoid granulomatous panniculitis and bullous
pemphigoid in a single patient. 2019;
35. Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, et al. Sarcoid-like
reactions in patients receiving modern melanoma treatment.Melanoma research . 2018;28(3):230.
36. Takamori S, Furubayashi N, Taguchi K, et al. Sarcoid‐like reaction
of the extrathoracic lymph node in a patient with lung adenocarcinoma
treated with pembrolizumab. Thoracic Cancer . 2021;
37. Yousuf H, Mekki R, Khan K, Hussain A. Pembrolizumab-Induced
Sarcoid-Like Reaction in a Patient With Lung Cancer. Cureus .
2020;12(12)
38. Muacevic A, Adler J, Yousuf H, Mekki R, Khan K, Hussain A.
Pembrolizumab-Induced Sarcoid-Like Reaction in a Patient With Lung
Cancer. Cureus . 2021;12(12)
39. van Baar ML, Guminski AD, Ferguson PM, Martin LK. Pembrolizumab for
cutaneous squamous cell carcinoma: report of a case of inoperable
squamous cell carcinoma with complete response to pembrolizumab
complicated by granulomatous inflammation. JAAD case reports .
2019;5(6):491.
40. Laroche A, Alarcon Chinchilla E, Bourgeault E, Doré M-A. Erythema
nodosum as the initial presentation of nivolumab-induced
sarcoidosis-like reaction. Journal of cutaneous medicine and
surgery . 2018;22(6):627-629.
41. Noguchi S, Kawachi H, Yoshida H, et al. Sarcoid-like granulomatosis
induced by nivolumab treatment in a lung cancer patient. Case
reports in oncology . 2018;11(2):562-566.
42. Paolini L, Poli C, Blanchard S, et al. Thoracic and cutaneous
sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal
monitoring of PD-1 and PD-L1 expression after stopping treatment.Journal for immunotherapy of cancer . 2018;6(1):1-5.
43. Mitchell MA, Hogan K, Amjadi K. Atezolizumab-induced sarcoid-like
granulomatous reaction in a patient with urothelial cell carcinoma.Immunotherapy . 2018;10(14):1189-1192.
44. Min ST, Nordman II, Tran HA. Hypercalcaemia due to sarcoidosis
during treatment with avelumab for metastatic merkel cell carcinoma.Case reports in oncology . 2019;12(2):639-643.
45. Sanderson E, Wimaleswaran H, Senko C, White S, McDonald CF.
Durvalumab induced sarcoid‐like pulmonary lymphadenopathy.Respirology case reports . 2020;8(3):e00542.
46. Sobash P, Desikan R, Kakkera K. SINGLE-DOSE DURVALUMAB INDUCED
SARCOIDOSIS-LIKE REACTION WITH GRANULOMA IN NON-SMALL CELL LUNG CANCER.Chest . 2020;158(4):A1518.
47. Rousseau PM, Raimbourg J, Robert M, Dansette D, Dréno B, Peuvrel L.
First case of cutaneous sarcoidosis within tattoos under durvalumab.International journal of dermatology . 2019;58(9):e168-e170.
48. Budnick I, Sturek J. Hilar and Mediastinal Lymphadenopathy Due to
Sarcoid-Like Reaction in Patient Receiving Durvalumab. TP36 TP036
WHAT DRUG CAUSED THAT? CASE REPORTS IN DRUG-INDUCED LUNG DISEASE .
American Thoracic Society; 2021:A2131-A2131.
49. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with
tumor response in patients with metastatic melanoma treated with
pembrolizumab. JAMA dermatology . 2016;152(1):45-51.
50. Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J. Vitiligo-like
lesions in patients receiving anti–programmed cell death-1 therapies
are distinct from spontaneously occurring active vitiligo. Journal
of the American Academy of Dermatology . 2018;78(1):e17-e18.
51. Nishino K, Ohe S, Kitamura M, et al. Nivolumab induced vitiligo-like
lesions in a patient with metastatic squamous cell carcinoma of the
lung. Journal of thoracic disease . 2018;10(6):E481.
52. Lolli C, Medri M, Ricci M, et al. Vitiligo-like lesions in a patient
treated with nivolumab for renal cell carcinoma. Medicine .
2018;97(52)
53. Billon E, Walz J, Brunelle S, et al. Vitiligo adverse event observed
in a patient with durable complete response after nivolumab for
metastatic renal cell carcinoma. Frontiers in oncology .
2019;9:1033.
54. Bulat V, Likic R, Bradic L, Speeckaert R, Azdajic MD.
Pembrolizumab‐induced vitiligo in a patient with lung adenocarcinoma: A
case report. British journal of clinical pharmacology . 2020;
55. Wolner Z, Marghoob A, Pulitzer M, Postow M, Marchetti M. A case
report of disappearing pigmented skin lesions associated with
pembrolizumab treatment for metastatic melanoma. British Journal
of Dermatology . 2018;178(1):265-269.
56. Yun SJ, Oh I-J, Park CK, et al. Vitiligo-like depigmentation after
pembrolizumab treatment in patients with non-small cell lung cancer: a
case report. Translational Lung Cancer Research . 2020;9(4):1585.
57. Rkman D, Likić R, Bebek M, Gnjidić M, Gamulin M. Skin autoimmunity
might be associated with increased efficacy of atezolizumab in
metastatic urothelial carcinoma: a case report. Croatian medical
journal . 2019;60(6):552.
58. Ebia MI, Choi JN. Dermatologic Reactions to Novel Immune Checkpoint
Inhibitors. Current Dermatology Reports . 2018;7(4):227-238.
59. Zafar Z, Vogler C, Hudali T, Bhattarai M. Nivolumab-associated acute
demyelinating encephalitis: a case report and literature review.Clinical medicine & research . 2019;17(1-2):29-33.
60. Kosche C, Mohindra N, Choi JN. Vitiligo in a patient undergoing
nivolumab treatment for non–small cell lung cancer. JAAD case
reports . 2018;4(10):1042-1044.
61. Donaldson M, Owen JL, Chae YK, Choi JN. Management of persistent
pruritus and lichenoid reaction secondary to nivolumab with narrowband
ultraviolet B phototherapy. Frontiers in oncology . 2018;8:405.
62. Bieber AK, Yin L, Sicco KL. Pruritus and Tense Bullae After
Discontinuation of Pembrolizumab in a Patient With Renal Cell Carcinoma.Jama . 2020;324(14):1453-1454.
63. Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T. Occurrence of
psoriasiform eruption during nivolumab therapy for primary oral mucosal
melanoma. JAMA dermatology . 2015;151(7):797-799.
64. De Bock M, Hulstaert E, Kruse V, Brochez L. Psoriasis vulgaris
exacerbation during treatment with a PD-1 checkpoint inhibitor: case
report and literature review. Case reports in dermatology .
2018;10(2):190-197.
65. Sapalidis K, Kosmidis C, Michalopoulos N, et al. Psoriatic arthritis
due to nivolumab administration a case report and review of the
literature. Respiratory medicine case reports . 2018;23:182-187.
66. Nigro O, Pinotti G, Gueli R, et al. Psoriatic arthritis induced by
anti-PD1 and treated with apremilast: a case report and review of the
literature. Immunotherapy . 2020;12(8):549-554.
67. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the
immunopathogenesis of psoriasis. Journal of Investigative
Dermatology . 2009;129(6):1339-1350.
68. Monsour EP, Pothen J, Balaraman R. A novel approach to the treatment
of pembrolizumab-induced psoriasis exacerbation: a case report.Cureus . 2019;11(10)
69. Siciliano MA, Dastoli S, d’Apolito M, et al. Pembrolizumab-Induced
Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a
Case Report. Frontiers in Oncology . 2020;10
70. Suzuki M, Matsumoto S, Takeda Y, Sugiyama H. Systemic Psoriasiform
Dermatitis Appeared after the Administration of Pembrolizumab.Internal Medicine . 2020;59(6):871-872.
71. Johnson D, Patel AB, Uemura MI, et al. IL17A blockade successfully
treated psoriasiform dermatologic toxicity from immunotherapy.Cancer immunology research . 2019;7(6):860-865.
72. Ma VT, Katzman CS, Palmbos PL, Patel RM, Gudjonsson JE, Alva AS.
NB-UVB phototherapy in the treatment of anti-PD-1 inhibitor induced
psoriasis: a case report. Current Problems in Cancer: Case
Reports . 2020;1:100004.
73. Yamamoto T. Anti-programmed cell death-1-induced plaque and guttate
psoriasis. Indian journal of dermatology . 2018;63(1):88.
74. Di Altobrando A, Bruni F, Alessandrini A, Starace M, Misciali C,
Piraccini BM. Severe de‐novo palmoplantar and nail psoriasis
complicating Nivolumab treatment for metastatic melanoma.Dermatologic therapy . 2020;33(3):e13363.
75. Politi A, Angelos D, Mauri D, Zarkavelis G, Pentheroudakis G. A case
report of psoriasis flare following immunotherapy: Report of an
important entity and literature review. SAGE open medical case
reports . 2020;8:2050313X19897707.
76. Ichiki N, Tanabe T, Hisada S, et al. A case of readministration of
nivolumab by treating with apremilast for psoriasiform eruption as irAE.Journal of Cutaneous Immunology and Allergy . 2021;4(3):67-68.
77. George A, George R. Nivolumab (PD-1 Inhibitor) Induced Exacerbation
of Psoriasis. Indian Dermatology Online Journal .
2020;11(2):261-262.
78. C Guven D, Kilickap S, Guner G, Taban H, Dizdar O. Development of de
novo psoriasis during nivolumab therapy in a patient with small cell
lung cancer. Journal of Oncology Pharmacy Practice .
2020;26(1):256-258.
79. Glinos GD, Fisher WS, Morr CS, Seminario-Vidal L. Nivolumab-induced
psoriasis successfully treated with risankizumab-rzaa in a patient with
stage III melanoma. JAAD Case Reports . 2021;11:74.
80. Om A, Cardon B, Cohen G. Psoriasiform eruption on the face and
extremities associated with nivolumab therapy. JAAD case reports .
2018;4(4):373.
81. Iijima S, Miyazaki K, Sato S, Kodama T. A case of de novo psoriasis
induced by atezolizumab in a patient with advanced lung cancer.Journal of Cutaneous Immunology and Allergy . 2019;2(6):178-179.
82. Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid.Anais brasileiros de dermatologia . 2019;94:133-146.
83. Rofe O, Bar‐Sela G, Keidar Z, Sezin T, Sadik C, Bergman R. Severe
bullous pemphigoid associated with pembrolizumab therapy for metastatic
melanoma with complete regression. Clinical and experimental
dermatology . 2017;42(3):309-312.
84. Thomsen K, Diernaes J, Øllegaard TH, Spaun E, Vestergaard C. Bullous
pemphigoid as an adverse reaction to pembrolizumab: two case reports.Case reports in dermatology . 2018;10(2):154-157.
85. Bezinelli LM, Eduardo FP, Migliorati CA, et al. A severe, refractory
case of mucous membrane pemphigoid after treatment with pembrolizumab:
brief communication. Journal of Immunotherapy .
2019;42(9):359-362.
86. Sun CW, Grossman SK, Aphale A, Hsu S. Pembrolizumab-induced bullous
pemphigoid. JAAD case reports . 2019;5(4):362.
87. Qiu C, Shevchenko A, Hsu S. Bullous pemphigoid secondary to
pembrolizumab mimicking toxic epidermal necrolysis. JAAD case
reports . 2020;6(5):400.
88. Hara K, Yamasaki K, Yamada S, Yatera K. Bullous pemphigoid in a
patient treated with pembrolizumab. Internal Medicine .
2020;59(1):139-140.
89. Muto Y, Namikawa K, Fujiwara Y, et al. Bullous pemphigoid induced by
pembrolizumab in a patient with non-small-cell lung cancer who achieved
durable complete response despite treatment cessation and long-term
corticosteroid administration: A case report. The Journal of
dermatology . 2020;47(1):e9-e11.
90. Cardona AF, Ruiz-Patiño A, Zatarain-Barron ZL, et al. Refractory
Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma
Treated with Pembrolizumab. Case Reports in Oncology .
2021;14(1):386-390.
91. Morris LM, Lewis HA, Cornelius LA, Chen DY, Rosman IS.
Neutrophil‐predominant bullous pemphigoid induced by checkpoint
inhibitors: A case series. Journal of cutaneous pathology .
2020;47(8):742-746.
92. Singer S, Nelson CA, Lian CG, Dewan AK, LeBoeuf NR. Nonbullous
pemphigoid secondary to PD-1 inhibition. JAAD case reports .
2019;5(10):898.
93. Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated
with anti–PD-1 and anti–PD-L1 therapy: a retrospective analysis
evaluating the clinical and histopathologic features, frequency, and
impact on cancer therapy. Journal of the American Academy of
Dermatology . 2018;79(6):1081-1088.
94. Panariello L, Fattore D, Annunziata MC, Piantedosi F, Gilli M,
Fabbrocini G. Bullous pemphigoid and nivolumab: Dermatologic management
to support and continue oncologic therapy. European Journal of
Cancer . 2018;103:284-286.
95. Wu X, Palvai S, Jalil A. Nivolumab-induced severe bullous pemphigoid
in a patient with renal cancer: a case report and literature review.Journal of Cancer Metastasis and Treatment . 2020;6
96. Palla AR, Smith E, Doll D. Bullous pemphigoid associated with the
480-mg nivolumab dose in a patient with metastatic renal cell carcinoma.Immunotherapy . 2019;11(14):1187-1192.
97. Sadik CD, Langan EA, Grätz V, Zillikens D, Terheyden P. Checkpoint
inhibition may trigger the rare variant of anti-LAD-1 IgG-positive,
anti-BP180 NC16A IgG-negative bullous pemphigoid. Frontiers in
immunology . 2019;10:1934.
98. Kosche C, Owen JL, Sadowsky LM, Choi JN. Bullous dermatoses
secondary to anti-PD-L1 agents: a case report and review of the
literature. Dermatology online journal . 2019;25(10)
99. Leavitt E, Holland V. A case of atezolizumab‐induced
photodistributed bullous pemphigoid. Dermatologic therapy .
2019;32(4):e12924.
100. Lopez AT, Geskin L. A case of nivolumab‐induced bullous pemphigoid:
Review of dermatologic toxicity associated with programmed cell death
protein‐1/programmed death ligand‐1 inhibitors and recommendations for
diagnosis and management. The Oncologist . 2018;23(10):1119.
101. Kudo F, Watanabe Y, Iwai Y, et al. Advanced lung adenocarcinoma
with nivolumab-associated dermatomyositis. Internal Medicine .
2018;57(15):2217-2221.
102. Kosche C, Stout M, Sosman J, Lukas RV, Choi JN. Dermatomyositis in
a patient undergoing nivolumab therapy for metastatic melanoma: a case
report and review of the literature. Melanoma research .
2020;30(3):313-316.
103. DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and
pathogenesis. Journal of the American Academy of Dermatology .
2020;82(2):267-281.
104. Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis:
role of cytokines and interferon. Current rheumatology reports .
2011;13(3):225-232.
105. Zarkavelis G, Mauri D, Karassa F, et al. The cancer immunotherapy
environment may confound the utility of anti-TIF-1γ in differentiating
between paraneoplastic and treatment-related dermatomyositis. Report of
a case and review of the literature. Contemporary Oncology .
2020;24(1):75.
106. Krathen M, Fiorentino D, Werth V. Dermatomyositis.Dermatologic Immunity . 2008;10:313-332.
107. Luo Y-B, Mastaglia FL. Dermatomyositis, polymyositis and
immune-mediated necrotising myopathies. Biochimica et Biophysica
Acta (BBA)-Molecular Basis of Disease . 2015;1852(4):622-632.
108. Messer A, Drozd B, Glitza IC, Lu H, Patel AB. Dermatomyositis
associated with nivolumab therapy for melanoma: a case report and review
of the literature. Dermatology online journal . 2020;26(8)
109. Shibata C, Kato J, Toda N, et al. Paraneoplastic dermatomyositis
appearing after nivolumab therapy for gastric cancer: a case report.Journal of medical case reports . 2019;13(1):1-6.
110. Osaki M, Tachikawa R, Ohira J, Hara S, Tomii K.
Anti-transcriptional intermediary factor 1-γ antibody-positive
dermatomyositis induced by nivolumab for lung adenocarcinoma: A case
report. Investigational new drugs . 2021;39(1):251-255.
111. Asano R, Shinoda K, Tsuda R, et al. Anti-TIF1γ antibody-positive
dermatomyositis in a 15-year-old boy with Epstein–Barr virus-related
nasopharyngeal cancer receiving nivolumab. Rheumatology .
2020;doi:10.1093/rheumatology/keaa832
112. Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M. Immune
checkpoint inhibitor-induced myositis: a case report and literature
review. Current rheumatology reports . 2019;21(4):1-9.
113. Marano A, Clarke J, Morse M, et al. Subacute cutaneous lupus
erythematosus and dermatomyositis associated with anti‐programmed cell
death 1 therapy. British Journal of Dermatology .
2019;181(3):580-583.
114. Liewluck T, Kao JC, Mauermann ML. PD-1 inhibitor-associated
myopathies: emerging immune-mediated myopathies. Journal of
Immunotherapy . 2018;41(4):208-211.
115. Takatsuki K, Yanagihara T, Egashira A, et al. A Rare Case of
Pembrolizumab-Induced Dermatomyositis in a Patient with Cancer of
Unknown Primary Origin. The American Journal of Case Reports .
2021;22:e930286-1.
116. Wiggins CJ, Chon SY. Dermatomyositis, pembrolizumab, and squamous
cell carcinoma of the lung. Taylor & Francis; 2021:120-121.
117. Berger M, Legeay A-L, Souci S, Streichenberger N, Thomas L, Dalle
S. Pembrolizumab-induced dermatomyositis in a patient with metastatic
melanoma. European Journal of Cancer . 2018;104:227-230.
118. Yamaguchi Y, Aso M, Nagasawa H, Wada M. Atezolizumab-associated
Dermatomyositis in Advanced Lung Small-cell Carcinoma. Internal
Medicine . 2021:6917-20.
119. Imai R, Ikemura S, Jinta T. Anti‐TIF1γ antibody‐positive
dermatomyositis associated with durvalumab administration in a patient
with lung and oesophageal cancers. Respirology case reports .
2021;9(4):e00736.
120. Kristjansdottir H, Steinsson K, Gunnarsson I, Gröndal G, Erlendsson
K, Alarcón‐Riquelme ME. Lower expression levels of the programmed death
1 receptor on CD4+ CD25+ T cells and correlation with the PD‐1.3 A
genotype in patients with systemic lupus erythematosus. Arthritis
& Rheumatism . 2010;62(6):1702-1711.
121. Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B,
Mitra A. Cutaneous lupus associated with pembrolizumab therapy for
advanced melanoma: a report of three cases. Melanoma research .
2019;29(3):338-341.
122. Shao K, McGettigan S, Elenitsas R, Chu EY. Lupus‐like cutaneous
reaction following pembrolizumab: An immune‐related adverse event
associated with anti‐PD‐1 therapy. Journal of cutaneous
pathology . 2018;45(1):74-77.
123. Jono M, Kinehara Y, Utsu Y, et al. Neuropsychiatric immune-related
adverse events induced by pembrolizumab in a patient with lung
adenocarcinoma and systemic lupus erythematosus. Internal
Medicine . 2020;59(4):569-572.
124. Kurokawa M, Naito S, Ito S, et al. Successful pembrolizumab
treatment in a patient with metastatic urothelial carcinoma and
underlying overlap syndrome involving systemic sclerosis and systemic
lupus erythematosus. IJU Case Reports . 2020;3(5):181-183.
125. Zitouni NB, Arnault J-P, Dadban A, Attencourt C, Lok CC, Chaby G.
Subacute cutaneous lupus erythematosus induced by nivolumab: two case
reports and a literature review. Melanoma research .
2019;29(2):212-215.
126. Tagliamento M, Grossi F, Paolino S, et al. Nivolumab treatment in
advanced lung cancer patient with chronic active hepatitis C and
systemic lupus erythematosus. Immunotherapy . 2019;11(10):873-879.
127. Wouters A, Durieux V, Kolivras A, Meert A-P, Sculier J-P. Bullous
lupus under Nivolumab treatment for lung cancer: A case report with
systematic literature review. Anticancer research .
2019;39(6):3003-3008.
128. Riano I, Cristancho C, Treadwell T. Stevens-Johnson Syndrome–Like
Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine
in a Patient With Metastatic Lung Cancer. Journal of investigative
medicine high impact case reports . 2020;8:2324709620914796.
129. Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens–Johnson
syndrome in non-melanoma patients. European Journal of Cancer .
2017;81:237-239.
130. Hwang A, Iskandar A, Dasanu CA. Stevens-Johnson syndrome
manifesting late in the course of pembrolizumab therapy. Journal
of Oncology Pharmacy Practice . 2019;25(6):1520-1522.
131. Ryu S, Jun I, Kim T-I, Seo KY, Kim EK. Pembrolizumab-induced
Stevens–Johnson Syndrome with Severe Ocular Complications. Ocular
Immunology and Inflammation . 2021:1-3.
132. Kimura H, Hasegawa A, Takei I, et al. Characteristic pathological
features of keratinocyte death in a case of Stevens–Johnson syndrome
manifested by an immune checkpoint inhibitor. Journal of the
European Academy of Dermatology and Venereology . 2021;35(2):e142-e145.
133. Robinson S, Saleh J, Curry J, Mudaliar K. Pembrolizumab-Induced
Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With
Metastatic Cervical Squamous Cell Carcinoma: A Case Report. The
American Journal of Dermatopathology . 2020;42(4):292-296.
134. Cai ZR, Lecours J, Adam J-P, et al. Toxic epidermal necrolysis
associated with pembrolizumab. Journal of Oncology Pharmacy
Practice . 2020;26(5):1259-1265.
135. OConnor C, Jordan E, O’Connell M. Atypical Stevens–Johnson
syndrome caused by pembrolizumab in the treatment of metastatic
melanoma–Are corticosteroids a safe treatment option? Journal of
Dermatology and Dermatologic Surgery . 2020;24(2):137.
136. Storandt MH, Seth R. A Case of Stevens-Johnson Syndrome/toxic
epidermal necrolysis in a patient receiving chemo-immunotherapy with
pemetrexed and pembrolizumab. Current Problems in Cancer: Case
Reports . 2021;3:100048.
137. Hsu T-J, Liu K-L. Stevens–Johnson syndrome and toxic epidermal
necrolysis related to immune checkpoint inhibitors: Two cases and
literature review. Dermatologica Sinica . 2020;38(4):236.
138. Kumar R, Bhandari S. Pembrolizumab induced toxic epidermal
necrolysis. Current problems in cancer . 2019:100478-100478.
139. Dasanu CA. Late-onset Stevens–Johnson syndrome due to nivolumab
use for hepatocellular carcinoma. Journal of Oncology Pharmacy
Practice . 2019;25(8):2052-2055.
140. Shibata A, Yoshikawa T, Makita S, Nakagawa S, Ueda Y, Akiyama M. A
case of recurrent Stevens-Johnson syndrome caused by nivolumab therapy.European Journal of Dermatology . 2019;1(1)
141. Gracia-Cazaña T, Padgett E, Calderero V, Oncins R.
Nivolumab-associated Stevens-Johnson syndrome in a patient with lung
cancer. Dermatology Online Journal . 2021;27(3)
142. Takeda Y, Kubota T, Choda Y, et al. Two Cases of Stevens-Johnson
Syndrome after Nivolumab Therapy for Gastric Cancer. Gan to Kagaku
ryoho Cancer & Chemotherapy . 2021;48(1):154-156.
143. Chirasuthat P, Chayavichitsilp P. Atezolizumab-induced
Stevens-Johnson syndrome in a patient with non-small cell lung
carcinoma. Case reports in dermatology . 2018;10(2):198-202.
144. Owosho AA, Randazzo J, Rosen EB, et al. Squamous cell carcinoma
associated with chronic graft versus host disease-like/lichen
planus-like lesion of the oral cavity in a patient managed for
metastatic melanoma with a PD-1 inhibitor pembrolizumab. Oral
oncology . 2016;63:e1.
145. Bhattacharyya I, Chehal H, Migliorati C. Severe oral erosive
lichenoid reaction to pembrolizumab therapy. Oral surgery, oral
medicine, oral pathology and oral radiology . 2020;130(5):e301-e307.
146. Shazib MA, Woo SB, Sroussi H, et al. Oral immune‐related adverse
events associated with PD‐1 inhibitor therapy: A case series. Oral
diseases . 2020;26(2):325-333.
147. Economopoulou P, Nicolatou-Galitis O, Kotsantis I, Psyrri A.
Nivolumab-related lichen planus of the lip in a patient with head and
neck cancer. Oral oncology . 2020;104:104623.
148. Enomoto Y, Nakatani H, Kondo S, Kasai T, Tsuchiya Y. Drug-induced
oral lichenoid reaction during nivolumab therapy. International
journal of oral and maxillofacial surgery . 2019;48(4):488-491.
149. Yamanaka S, Nakao K, Ninomiya A, et al. A case of oral lichenoid
reaction during nivolumab therapy. Journal of Oral and
Maxillofacial Surgery, Medicine, and Pathology . 2020;32(6):521-524.
150. Spinelli A, Gissi DB, Rossi R, Gabusi A. A Case of
Nivolumab-Associated Oral Lichenoid Lesions. Multidisciplinary
Digital Publishing Institute Proceedings . 2019;35(1):76.